325 related articles for article (PubMed ID: 26213107)
1. CD70: An emerging target in cancer immunotherapy.
Jacobs J; Deschoolmeester V; Zwaenepoel K; Rolfo C; Silence K; Rottey S; Lardon F; Smits E; Pauwels P
Pharmacol Ther; 2015 Nov; 155():1-10. PubMed ID: 26213107
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of CD70 and CD27.
Wajant H
Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
[TBL] [Abstract][Full Text] [Related]
3. Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer.
Jacobs J; Zwaenepoel K; Rolfo C; Van den Bossche J; Deben C; Silence K; Hermans C; Smits E; Van Schil P; Lardon F; Deschoolmeester V; Pauwels P
Oncotarget; 2015 May; 6(15):13462-75. PubMed ID: 25951351
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma.
Miller J; Eisele G; Tabatabai G; Aulwurm S; von Kürthy G; Stitz L; Roth P; Weller M
J Neurosurg; 2010 Aug; 113(2):280-5. PubMed ID: 19961309
[TBL] [Abstract][Full Text] [Related]
5. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology.
Nolte MA; van Olffen RW; van Gisbergen KP; van Lier RA
Immunol Rev; 2009 May; 229(1):216-31. PubMed ID: 19426224
[TBL] [Abstract][Full Text] [Related]
6. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential.
van de Ven K; Borst J
Immunotherapy; 2015; 7(6):655-67. PubMed ID: 26098609
[TBL] [Abstract][Full Text] [Related]
7. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD70 for human therapeutic use.
Boursalian TE; McEarchern JA; Law CL; Grewal IS
Adv Exp Med Biol; 2009; 647():108-19. PubMed ID: 19760069
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
[TBL] [Abstract][Full Text] [Related]
10. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
11. Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.
Arimoto-Miyamoto K; Kadowaki N; Kitawaki T; Iwata S; Morimoto C; Uchiyama T
Immunology; 2010 May; 130(1):137-49. PubMed ID: 20201989
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice.
Makino F; Ito J; Abe Y; Harada N; Kamachi F; Yagita H; Takahashi K; Okumura K; Akiba H
Am J Respir Cell Mol Biol; 2012 Sep; 47(3):298-305. PubMed ID: 22499851
[TBL] [Abstract][Full Text] [Related]
13. CD8+ T cells produce the chemokine CXCL10 in response to CD27/CD70 costimulation to promote generation of the CD8+ effector T cell pool.
Peperzak V; Veraar EA; Xiao Y; Babala N; Thiadens K; Brugmans M; Borst J
J Immunol; 2013 Sep; 191(6):3025-36. PubMed ID: 23940275
[TBL] [Abstract][Full Text] [Related]
14. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
15. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity.
Keller AM; Schildknecht A; Xiao Y; van den Broek M; Borst J
Immunity; 2008 Dec; 29(6):934-46. PubMed ID: 19062317
[TBL] [Abstract][Full Text] [Related]
16. γδ T cells develop, respond and survive - with a little help from CD27.
Born WK; O'Brien RL
Eur J Immunol; 2011 Jan; 41(1):26-8. PubMed ID: 21182073
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
18. Direct cellular communications between CD45R0 and CD45RA T cell subsets via CD27/CD70.
Agematsu K; Kobata T; Sugita K; Hirose T; Schlossman SF; Morimoto C
J Immunol; 1995 Apr; 154(8):3627-35. PubMed ID: 7706706
[TBL] [Abstract][Full Text] [Related]
19. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7).
Starzer AM; Berghoff AS
ESMO Open; 2020 Mar; 4(Suppl 3):e000629. PubMed ID: 32152062
[TBL] [Abstract][Full Text] [Related]
20. CD27/CD70 interaction directly drives B cell IgG and IgM synthesis.
Agematsu K; Kobata T; Yang FC; Nakazawa T; Fukushima K; Kitahara M; Mori T; Sugita K; Morimoto C; Komiyama A
Eur J Immunol; 1995 Oct; 25(10):2825-9. PubMed ID: 7589078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
